{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T21:04:59Z","timestamp":1789247099269,"version":"build-2803163510"},"reference-count":175,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.intimp.2026.116867","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:30:20Z","timestamp":1778891420000},"page":"116867","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The evolution of CAR therapies across oncology and autoimmunity: mechanistic insights and therapeutic innovations"],"prefix":"10.1016","volume":"182","author":[{"given":"Eslam E.","family":"Abd El-Fattah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"Hamdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameh S.M.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed I.","family":"Husseiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.intimp.2026.116867_bb0005","doi-asserted-by":"crossref","first-page":"7159","DOI":"10.1073\/pnas.86.18.7159","article-title":"Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells","volume":"86","author":"Barnd","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2026.116867_bb0010","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2026.116867_bb0015","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for Cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2026.116867_bb0020","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s12032-025-02923-x","article-title":"CAR T-cell therapy in hematologic and solid malignancies: mechanisms, clinical applications, and future directions","volume":"42","author":"Kuttiappan","year":"2025","journal-title":"Med. Oncol. (Northwood, London, England)."},{"key":"10.1016\/j.intimp.2026.116867_bb0025","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1200\/JCO.22.02345","article-title":"CAR T-cells for cure in pediatric B-ALL","volume":"41","author":"Gardner","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116867_bb0030","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0035","doi-asserted-by":"crossref","first-page":"1664403","DOI":"10.3389\/fimmu.2025.1664403","article-title":"Non-signaling but all important: how the linker, hinge, and transmembrane domains in the CAR hold it all together","volume":"16","author":"Bernard","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0040","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.3390\/cancers15133476","article-title":"Fine-tuning through generations: advances in structure and production of CAR-T therapy","volume":"15","author":"Zheng","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.116867_bb0045","doi-asserted-by":"crossref","first-page":"1335424","DOI":"10.3389\/fimmu.2024.1335424","article-title":"Recent Advances on CAR-T Signaling Pave the Way for Prolonged Persistence and New Modalities in Clinic","volume":"15","author":"Smirnov","year":"2024","journal-title":"Front. Immunol"},{"key":"10.1016\/j.intimp.2026.116867_bb0050","doi-asserted-by":"crossref","first-page":"1581210","DOI":"10.3389\/fimmu.2025.1581210","article-title":"Mathematical models and computational approaches in CAR-T therapeutics","volume":"16","author":"Putignano","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0055","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003354","article-title":"4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells","volume":"9","author":"Roselli","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.116867_bb0060","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/mto.2016.14","article-title":"CAR models: next-generation CAR modifications for enhanced T-cell function","volume":"3","author":"Abate-Daga","year":"2016","journal-title":"Mol. Therapy Oncol."},{"key":"10.1016\/j.intimp.2026.116867_bb0065","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3324\/haematol.2019.231183","article-title":"CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells","volume":"106","author":"Guercio","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.intimp.2026.116867_bb0070","doi-asserted-by":"crossref","DOI":"10.4110\/in.2025.25.e43","article-title":"Cytokine engineering in CAR-T cell therapy: next-generation strategies","volume":"25","author":"Kim","year":"2025","journal-title":"Immune Netw."},{"key":"10.1016\/j.intimp.2026.116867_bb0075","series-title":"Advancement in CAR T-Cell Therapy in Tumors: Current Challenges and Future Directions","first-page":"25","article-title":"CAR T-cell therapy: Basic principles and mechanisms","author":"Rai","year":"2026"},{"key":"10.1016\/j.intimp.2026.116867_bb0080","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-025-03938-0","article-title":"Advancements and challenges in CAR-T cell therapy for solid tumors: a comprehensive review of antigen targets, strategies, and future directions","volume":"25","author":"Zhu","year":"2025","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.intimp.2026.116867_bb0085","doi-asserted-by":"crossref","first-page":"1260470","DOI":"10.3389\/fimmu.2023.1260470","article-title":"Advancing CART therapy for acute myeloid leukemia: recent breakthroughs and strategies for future development","volume":"14","author":"Perez-Amill","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0090","first-page":"2898","article-title":"Advancing CAR T-Cell Therapy in Solid Tumors: Current Landscape and Future Directions","volume":"17","author":"Rafii","year":"2025"},{"key":"10.1016\/j.intimp.2026.116867_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00453","article-title":"CART immunotherapy: development, success, and translation to malignant gliomas and other solid tumors","volume":"8","author":"Filley","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.116867_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2025.103164","article-title":"CAR T-cell therapy in autoimmune diseases: opportunities and challenges, with implications for RA","volume":"98","author":"Hojati Shargh","year":"2026","journal-title":"Tissue Cell"},{"key":"10.1016\/j.intimp.2026.116867_bb0105","article-title":"CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0110","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2174\/0113892010257212231001082741","article-title":"FDA-approved CAR T-cell therapy: a decade of Progress and challenges","volume":"25","author":"Ong","year":"2024","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.intimp.2026.116867_bb0115","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.3390\/ijms22042150","article-title":"A review of clinical outcomes of CAR T-cell therapies for B-acute lymphoblastic leukemia","volume":"22","author":"Martino","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.116867_bb0120","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11864-025-01305-9","article-title":"The improving outcomes in relapsed-refractory diffuse large B cell lymphoma: the role of CAR T-cell therapy","volume":"26","author":"Milunovi\u0107","year":"2025","journal-title":"Curr. Treat. Options in Oncol."},{"key":"10.1016\/j.intimp.2026.116867_bb0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/hemato6010003","article-title":"Real-World Outcomes of Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Third-Line Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Single-Center Study","volume":"6","author":"Sridhar","year":"2025","journal-title":"Hemato"},{"key":"10.1016\/j.intimp.2026.116867_bb0130","doi-asserted-by":"crossref","first-page":"29843","DOI":"10.18632\/oncotarget.25688","article-title":"CD19 directed CAR T cell therapy in diffuse large B-cell lymphoma","volume":"9","author":"Quint\u00e1s-Cardama","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2026.116867_bb0135","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116867_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20406207221142133","article-title":"CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma","volume":"13","author":"Mohty","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.intimp.2026.116867_bb0145","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.clml.2024.10.009","article-title":"SOHO state of the art updates and next questions | the current state of CAR T-cell therapy and bispecific antibodies in mantle cell lymphoma","volume":"25","author":"Weiss","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.intimp.2026.116867_bb0150","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1182\/bloodadvances.2023010856","article-title":"Beyond BCMA: newer immune targets in myeloma","volume":"8","author":"Tan","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2026.116867_bb0155","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev-cancerbio-061421-014236","article-title":"Next-generation therapies for multiple myeloma","volume":"8","author":"Meermeier","year":"2024","journal-title":"Ann. Rev. Cancer Biol."},{"key":"10.1016\/j.intimp.2026.116867_bb0160","doi-asserted-by":"crossref","first-page":"1433774","DOI":"10.3389\/fimmu.2024.1433774","article-title":"Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy","volume":"15","author":"Fu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1460437","article-title":"Finding potential targets in cell-based immunotherapy for handling the challenges of acute myeloid leukemia","volume":"15","author":"Kheirkhah","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0170","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00277-026-06742-6","article-title":"Next-generation CAR-T therapy for acute myeloid leukemia: bridging innovation with clinical translation","volume":"105","author":"Zhao","year":"2026","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.intimp.2026.116867_bb0175","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41375-024-02444-y","article-title":"Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy","volume":"38","author":"Lei","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2026.116867_bb0180","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/bloodadvances.2023012263","article-title":"CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?","volume":"9","author":"Maciocia","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2026.116867_bb0185","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.116867_bb0190","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.intimp.2026.116867_bb0195","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12943-025-02334-6","article-title":"Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy","volume":"24","author":"Lu","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2026.116867_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies","volume":"10","author":"Xu","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117252","article-title":"Antigen escape in CAR-T cell therapy: mechanisms and overcoming strategies","volume":"178","author":"Lin","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2026.116867_bb0210","doi-asserted-by":"crossref","first-page":"1546172","DOI":"10.3389\/fimmu.2025.1546172","article-title":"Tandem CAR-T cell therapy: recent advances and current challenges","volume":"16","author":"G\u00f3mez-Melero","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0215","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/blood.2023020621","article-title":"CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL","volume":"143","author":"Ghorashian","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116867_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion \u2013 An Essential But Undervalued Part of the Chimeric Antigen Receptor t-Cell Therapy Cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0225","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.922212","article-title":"Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric antigen receptor T-cell therapy","volume":"13","author":"Gong","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0230","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ymthe.2024.11.017","article-title":"Optimizing CAR-T treatment: a T(2)EVOLVE guide to raw and starting material selection","volume":"33","author":"Navarro","year":"2025","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.intimp.2026.116867_bb0235","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/cells14010041","article-title":"CAR-T therapy beyond B-cell hematological malignancies","volume":"14","author":"Canichella","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2026.116867_bb0240","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3390\/cimb47050381","article-title":"The struggle between chimeric antigen receptor T-cell therapy and neurological complications in acute lymphoblastic leukemia treatment","volume":"47","author":"Kubick","year":"2025","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.intimp.2026.116867_bb0245","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/17474086.2022.2081147","article-title":"Idecabtagene Vicleucel Versus Ciltacabtagene Autoleucel: A Sophie\u2019s Choice for Patients with Relapsed Refractory Multiple Myeloma","volume":"15","author":"Davis","year":"2022","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.intimp.2026.116867_bb0250","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.116867_bb0255","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40265-022-01697-0","article-title":"BCMA-targeted biologic therapies: the next standard of Care in Multiple Myeloma Therapy","volume":"82","author":"Paul","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2026.116867_bb0260","article-title":"Targeting BCMA in multiple myeloma: a comprehensive review of immunotherapeutic strategies and clinical outcomes","volume":"33","author":"Chan","year":"2025","journal-title":"Mol. Therapy Oncol."},{"key":"10.1016\/j.intimp.2026.116867_bb0265","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s43556-025-00401-4","article-title":"CAR-engineered cell therapies: current understandings and future perspectives","volume":"7","author":"Bayat","year":"2026","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.intimp.2026.116867_bb0270","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.3390\/cancers17243892","article-title":"The rise of fine-tuned CAR-based therapies against acute myeloid leukemia","volume":"17","author":"Segura Tudela","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.116867_bb0275","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12967-023-04041-6","article-title":"Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility","volume":"21","author":"Celichowski","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2026.116867_bb0280","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2026.116867_bb0285","first-page":"644","volume":"65","author":"Tashiro","year":"2024","journal-title":"[Rinsho ketsueki] Jap. J. Clin. Hematol."},{"key":"10.1016\/j.intimp.2026.116867_bb0290","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf\u2019allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2026.116867_bb0295","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.3390\/biom15101407","article-title":"Advancing CAR-T therapy for solid tumors: from barriers to clinical progress","volume":"15","author":"Smirnov","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.intimp.2026.116867_bb0300","doi-asserted-by":"crossref","first-page":"1434495","DOI":"10.3389\/fonc.2024.1434495","article-title":"EGFRVIII and EGFR targeted chimeric antigen receptor T cell therapy in glioblastoma","volume":"14","author":"Sterner","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.116867_bb0305","first-page":"1","article-title":"Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13R\u03b12 are effective against heterogeneous glioblastoma","volume":"5","author":"Schmidts","year":"2022","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.intimp.2026.116867_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1142597","article-title":"The peculiar challenge of bringing CAR-T cells into the brain: perspectives in the clinical application to the treatment of pediatric central nervous system tumors","volume":"14","author":"Del Baldo","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0315","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2159-8290.CD-24-1465","article-title":"Evolving CAR T-cell therapy to overcome the barriers in treating pediatric central nervous system tumors","volume":"15","author":"Timpanaro","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2026.116867_bb0320","doi-asserted-by":"crossref","first-page":"377","DOI":"10.31083\/j.fbl2911377","article-title":"Regulatory T-cells: the face-off of the immune balance","volume":"29","author":"Singer","year":"2024","journal-title":"Front. Biosci. (Landmark Ed)"},{"key":"10.1016\/j.intimp.2026.116867_bb0325","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1016\/j.ymthe.2024.07.020","article-title":"Armored bicistronic CAR T cells with dominant-negative TGF-\u03b2 receptor II to overcome resistance in glioblastoma","volume":"32","author":"Li","year":"2024","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.intimp.2026.116867_bb0330","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13045-024-01544-7","article-title":"Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives","volume":"17","author":"Lin","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.116867_bb0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/15330338221132927","article-title":"Adverse cardiac effects of CAR T-cell therapy: characteristics, surveillance, management, and future research directions","volume":"21","author":"Dalal","year":"2022","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.intimp.2026.116867_bb0340","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116867_bb0345","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.3390\/jcm14093189","article-title":"Carcinoembryonic antigen (CEA): origin, role in oncology, and concentrations in serum and peritoneal fluid","volume":"14","author":"Niedzielska","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.intimp.2026.116867_bb0350","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.978195","article-title":"CAR T-cells for colorectal cancer immunotherapy: ready to go?","volume":"13","author":"Ghazi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0355","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/jamaoncol.2024.3891","article-title":"Chimeric antigen receptor T cells targeting CD19 and GCC in metastatic colorectal cancer: a nonrandomized clinical trial","volume":"10","author":"Chen","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2026.116867_bb0360","article-title":"Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2026.116867_bb0365","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41571-025-01077-z","article-title":"The tumour microenvironment in pancreatic cancer\u2014new clinical challenges, but more opportunities","volume":"22","author":"Kung","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116867_bb0370","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/14712598.2021.1843628","article-title":"Mesothelin-targeted CAR-T cell therapy for solid tumors","volume":"21","author":"Klampatsa","year":"2021","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.intimp.2026.116867_bb0375","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3390\/cancers14061550","article-title":"Mesothelin: an immunotherapeutic target beyond solid tumors","volume":"14","author":"Faust","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.116867_bb0380","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3390\/cancers12061389","article-title":"Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer","volume":"12","author":"Henze","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.116867_bb0385","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2517786122","article-title":"Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell-engineered mesothelin-redirected CAR-NKT cells","volume":"122","author":"Li","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2026.116867_bb0390","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.3390\/cells14161285","article-title":"Claudin18.2 as a promising therapeutic target in gastric cancer","volume":"14","author":"Poniewierska-Baran","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2026.116867_bb0395","article-title":"CAR-T cell therapy: advances in digestive system malignant tumors","volume":"32","author":"Xu","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.intimp.2026.116867_bb0400","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1489649","article-title":"CAR-T cell therapy for hepatocellular carcinoma: current trends and challenges","volume":"15","author":"Zhou","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0405","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.3390\/ijms25052631","article-title":"Chimeric antigen receptor T cell therapy for hepatocellular carcinoma: where do we stand?","volume":"25","author":"Aggeletopoulou","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.116867_bb0410","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2559.2007.02635.x","article-title":"Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique","volume":"50","author":"Mhawech-Fauceglia","year":"2007","journal-title":"Histopathology"},{"key":"10.1016\/j.intimp.2026.116867_bb0415","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.7150\/thno.76854","article-title":"Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy","volume":"12","author":"Liu","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.intimp.2026.116867_bb0420","first-page":"1","article-title":"Spatial immune profiling of bone-metastatic castration-resistant prostate cancer reveals radium-223 immunomodulates the bone-tumor microenvironment","author":"Corn","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.intimp.2026.116867_bb0425","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3390\/cancers14030503","article-title":"Chimeric antigen receptor T-cell therapy in metastatic castrate-resistant prostate cancer","volume":"14","author":"Perera","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.116867_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104785","article-title":"A new approach to the treatment of ovarian cancer: the application of CAR-T cell therapy","volume":"213","author":"Yang","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.intimp.2026.116867_bb0435","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/cancers18010086","article-title":"Nanomedicine in ovarian cancer: advances in imaging, targeted delivery, and theranostic therapeutic platforms","volume":"18","author":"Bartusik-Aebisher","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.116867_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100804","article-title":"Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells","volume":"6","author":"Li","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.intimp.2026.116867_bb0445","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126345","article-title":"ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models","volume":"4","author":"Wallstabe","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.intimp.2026.116867_bb0450","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000200","article-title":"Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets","volume":"2","author":"Aguiar","year":"2017","journal-title":"ESMO Open."},{"key":"10.1016\/j.intimp.2026.116867_bb0455","article-title":"The association of efficacy with PD-1\/PD-L1 inhibition and tumor mutational burden in advanced nonsmall cell lung cancer: a PRISMA-guided literature review and meta-analysis","volume":"101","author":"Yu","year":"2022","journal-title":"Medicine"},{"key":"10.1016\/j.intimp.2026.116867_bb0460","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01464-y","article-title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer","volume":"16","author":"Rudin","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.116867_bb0465","first-page":"192","article-title":"Current advances in CAR T cell therapy for malignant mesothelioma","volume":"2","author":"Klampatsa","year":"2020","journal-title":"J. Cell. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0470","doi-asserted-by":"crossref","first-page":"62730","DOI":"10.18632\/oncotarget.17528","article-title":"Driving better and safer HER2-specific CARs for cancer therapy","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2026.116867_bb0475","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.3390\/cancers15071987","article-title":"Emerging targeted therapies for HER2-positive breast cancer","volume":"15","author":"Mercogliano","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.116867_bb0480","first-page":"422","article-title":"Targeted chemotherapy via HER2-based chimeric antigen receptor (CAR) engineered T-cell membrane coated polymeric nanoparticles","volume":"34","author":"Yaman","year":"2024","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.intimp.2026.116867_bb0485","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008566","article-title":"Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity","volume":"12","author":"Shabaneh","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.116867_bb0490","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-025-01736-9","article-title":"Targeting triple-negative breast cancer using cord-blood CD34(+) HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity","volume":"18","author":"Li","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.116867_bb0495","article-title":"GD2 targeting CAR T cells for neuroblastoma","volume":"4","author":"Anderson","year":"2024","journal-title":"EJC Paediatr. Oncol."},{"key":"10.1016\/j.intimp.2026.116867_bb0500","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/pbc.26097","article-title":"Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults","volume":"63","author":"Dobrenkov","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.intimp.2026.116867_bb0505","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10555-025-10294-y","article-title":"B7-H3 in the tumor microenvironment: implications for CAR T cell therapy in pediatric solid tumors","volume":"44","author":"Jansen","year":"2025","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.intimp.2026.116867_bb0510","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3390\/cells14151209","article-title":"B7-H3 in cancer immunotherapy-prospects and challenges: a review of the literature","volume":"14","author":"Mielcarska","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2026.116867_bb0515","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.3390\/cancers15164035","article-title":"Targeted therapy for EWS-FLI1 in Ewing sarcoma","volume":"15","author":"Gong","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.116867_bb0520","article-title":"Programmable iPSC-derived CAR-NK vesicles remodel the immune microenvironment and eradicate tumors","volume":"7","author":"Zhang","year":"2026","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.intimp.2026.116867_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218014","article-title":"Cell adhesion molecule ITGB2 promotes CAR-T cell therapy in B-cell malignancies","volume":"633","author":"Su","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2026.116867_bb0530","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12943-025-02411-w","article-title":"Advances and obstacles of T cell-based immunotherapy in gynecological malignancies","volume":"24","author":"Zhao","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2026.116867_bb0535","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008179","article-title":"Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16","volume":"12","author":"Casey","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.116867_bb0540","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.3390\/ijms21114067","article-title":"From malignant progression to therapeutic targeting: current insights of mesothelin in pancreatic ductal adenocarcinoma","volume":"21","author":"Montemagno","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.116867_bb0545","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.3390\/biomedicines13102545","article-title":"CAR-T cell therapy for prostate cancer: current advances and future perspectives","volume":"13","author":"Calabr\u00f2","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.intimp.2026.116867_bb0550","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3390\/vaccines12030276","article-title":"Mechanism of action of oral Salmonella-based vaccine to prevent and reverse type 1 diabetes in NOD mice","volume":"12","author":"Cobb","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.intimp.2026.116867_bb0555","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3390\/vaccines13040405","article-title":"Salmonella-based vaccine: a promising strategy for type 1 diabetes","volume":"13","author":"Singer","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.intimp.2026.116867_bb0560","doi-asserted-by":"crossref","first-page":"1740385","DOI":"10.3389\/fimmu.2025.1740385","article-title":"Oral tolerogenic vaccine combined with gastrin restores immune tolerance and beta-cell function in NOD mice with type 1 diabetes","volume":"16","author":"Cobb","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2026.114988","article-title":"CAR Treg therapies for neurodegenerative diseases","volume":"29","author":"Stein","year":"2026","journal-title":"iScience"},{"key":"10.1016\/j.intimp.2026.116867_bb0570","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/eji.202049123","article-title":"Mechanisms of exTreg induction","volume":"51","author":"Saxena","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0575","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088318","article-title":"The Treg-specific demethylated region stabilizes Foxp3 expression independently of NF-\u03baB signaling","volume":"9","author":"Schreiber","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2026.116867_bb0580","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2020.00300","article-title":"Development of quantitative methylation-specific droplet digital PCR (ddMSP) for assessment of natural Tregs","volume":"11","author":"Husseiny","year":"2020","journal-title":"Front. Genet."},{"key":"10.1016\/j.intimp.2026.116867_bb0585","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116867_bb0590","article-title":"Hypogammaglobulinemia secondary to B-cell depleting therapies in neuroimmunology: comparing management strategies","volume":"9","author":"Kelly","year":"2023","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.intimp.2026.116867_bb0595","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-025-01769-0","article-title":"Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases","volume":"19","author":"Chen","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.116867_bb0600","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/ar3433","article-title":"Mechanisms of B cell autoimmunity in SLE","volume":"13","author":"D\u00f6rner","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2026.116867_bb0605","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/pathophysiology32040061","article-title":"Immunopathogenesis of systemic lupus erythematosus: interplay of innate and adaptive immunity, microbiome Dysbiosis, and emerging therapeutic targets","volume":"32","author":"Ahmed","year":"2025","journal-title":"Pathophysiology"},{"key":"10.1016\/j.intimp.2026.116867_bb0610","article-title":"CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon","volume":"16","author":"Wu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0615","doi-asserted-by":"crossref","first-page":"1476859","DOI":"10.3389\/fimmu.2024.1476859","article-title":"CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives","volume":"15","author":"Zhou","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0620","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26914","article-title":"Hypogammaglobulinemia due to CAR T-cell therapy","volume":"65","author":"Doan","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.intimp.2026.116867_bb0625","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.938785","article-title":"Involvement of B cells in the development of systemic sclerosis","volume":"13","author":"Yoshizaki","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0630","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.933468","article-title":"Role of B-cell in the pathogenesis of systemic sclerosis","volume":"13","author":"Thoreau","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0635","doi-asserted-by":"crossref","DOI":"10.1111\/imr.70059","article-title":"Role of fibroblast-immune crosstalk in kidney, lung, and skin tertiary lymphoid structures","volume":"334","author":"Cross","year":"2025","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2026.116867_bb0640","doi-asserted-by":"crossref","first-page":"2275457","DOI":"10.1080\/21645515.2023.2275457","article-title":"Building safety into CAR-T therapy","volume":"19","author":"Peters","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.intimp.2026.116867_bb0645","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200080","article-title":"CAR-T cell-mediated B-cell depletion in central nervous system autoimmunity","volume":"10","author":"Gupta","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.intimp.2026.116867_bb0650","series-title":"Handbook of Clinical Neurology","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/B978-0-323-90887-0.00012-2","article-title":"Chapter 24 - the future unfolded: CAR T cells and the transformation of treatment algorithms in autoimmune neurology","author":"Mougiakakos","year":"2026"},{"key":"10.1016\/j.intimp.2026.116867_bb0655","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaut.2018.05.003","article-title":"Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells","volume":"92","author":"Kim","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2026.116867_bb0660","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12974-024-03262-w","article-title":"MOG-specific CAR Tregs: a novel approach to treat multiple sclerosis","volume":"21","author":"Frikeche","year":"2024","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.intimp.2026.116867_bb0665","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41392-025-02415-4","article-title":"Multiple sclerosis: molecular pathogenesis and therapeutic intervention","volume":"10","author":"Boutitah-Benyaich","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2026.116867_bb0670","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0675","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.intimp.2026.116867_bb0680","doi-asserted-by":"crossref","first-page":"1562662","DOI":"10.3389\/fimmu.2025.1562662","article-title":"Chimeric autoantibody receptor T cells specifically eliminate graves\u2019 disease autoreactive B cells","volume":"16","author":"Cheever","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0685","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.70298","article-title":"Chimeric antigen receptor T-cell therapy and autoimmune diseases in the nervous system","volume":"13","author":"Yao","year":"2025","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.intimp.2026.116867_bb0690","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0695","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.4103\/NRR.NRR-D-24-01011","article-title":"Novel therapies for myasthenia gravis: translational research from animal models to clinical application","volume":"21","author":"Sorrenti","year":"2026","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.intimp.2026.116867_bb0700","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a007641","article-title":"The pathogenesis and natural history of type 1 diabetes","volume":"2","author":"Atkinson","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.intimp.2026.116867_bb0705","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fendo.2017.00343","article-title":"T cell-mediated Beta cell destruction: autoimmunity and alloimmunity in the context of type 1 diabetes","volume":"8","author":"Burrack","year":"2017","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.intimp.2026.116867_bb0710","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1509956","article-title":"From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases","volume":"15","author":"Bulliard","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0715","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.vaccine.2014.02.070","article-title":"An oral vaccine for type 1 diabetes based on live attenuated Salmonella","volume":"32","author":"Husseiny","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2026.116867_bb0720","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.1016\/j.vaccine.2018.10.101","article-title":"Factors affecting Salmonella-based combination immunotherapy for prevention of type 1 diabetes in non-obese diabetic mice","volume":"36","author":"Husseiny","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2026.116867_bb0725","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adp6519","article-title":"CAR Treg cells mediate linked suppression and infectious tolerance in islet transplantation in mice","volume":"17","author":"Wardell","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2026.116867_bb0730","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3389\/fimmu.2019.00320","article-title":"Reversal of new onset type 1 diabetes by oral Salmonella-based combination therapy and mediated by regulatory T-cells in NOD mice","volume":"10","author":"Mbongue","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0735","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.667897","article-title":"Oral Salmonella msbb mutant as a carrier for a Salmonella-based vaccine for prevention and reversal of type 1 diabetes","volume":"12","author":"Cobb","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0740","article-title":"Regulatory T cell dysfunction and immunotherapeutic breakthroughs in type 1 diabetes","volume":"16","author":"Zhou","year":"2025","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.intimp.2026.116867_bb0745","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0303863","article-title":"Reversal of diabetes by an oral Salmonella-based vaccine in acute and progressive diabetes in NOD mice","volume":"19","author":"Cobb","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2026.116867_bb0750","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s12015-023-10668-1","article-title":"Chimeric antigen receptor (CAR)-based cell therapy for type 1 diabetes mellitus (T1DM); current progress and future approaches","volume":"20","author":"Mohammadi","year":"2024","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.intimp.2026.116867_bb0755","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/1073984","article-title":"Intestinal immune imbalance is an alarm in the development of IBD","volume":"2023","author":"Hu","year":"2023","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.intimp.2026.116867_bb0760","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.it.2023.04.005","article-title":"Engineered Treg cells as putative therapeutics against inflammatory diseases and beyond","volume":"44","author":"Bittner","year":"2023","journal-title":"Trends Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0765","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2217\/ijr.12.7","article-title":"Living life without B cells: is repeated B-cell depletion a safe and effective long-term treatment plan for rheumatoid arthritis?","volume":"7","author":"Chen","year":"2012","journal-title":"Int. J. Clin. Rheumtol."},{"key":"10.1016\/j.intimp.2026.116867_bb0770","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2026.116867_bb0775","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020287","article-title":"CAR-T regulatory (CAR-Treg) cells: engineering and applications","volume":"10","author":"Arjomandnejad","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.intimp.2026.116867_bb0780","doi-asserted-by":"crossref","first-page":"11898","DOI":"10.3390\/ijms262411898","article-title":"The current landscape of modular CAR T cells","volume":"26","author":"Joechner","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.116867_bb0785","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1409665","article-title":"Modular (universal) CAR-T platforms in vivo: a comprehensive systematic review","volume":"15","author":"Mohammad","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0790","series-title":"Development and Characterization of Universal and Modular Bispecific Immune Cell Engagers for cancer Immunotherapy: Lmu","author":"Sur\u00f3wka","year":"2025"},{"key":"10.1016\/j.intimp.2026.116867_bb0795","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2026.116867_bb0800","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.intimp.2026.116867_bb0805","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1\u2013and CTLA-4\u2013based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2026.116867_bb0810","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1053\/j.seminhematol.2025.08.003","article-title":"The immunotherapy landscape in AML: defining knowledge gaps toward rational combinatorial strategies","author":"Subklewe","year":"2025","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.intimp.2026.116867_bb0815","doi-asserted-by":"crossref","first-page":"1545270","DOI":"10.3389\/fimmu.2025.1545270","article-title":"SynNotch CAR-T cell, when synthetic biology and immunology meet again","volume":"16","author":"Shirzadian","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0820","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2026.116867_bb0825","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116867_bb0830","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.intimp.2026.116867_bb0835","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable manufacturing of CAR T cells for cancer immunotherapy","volume":"2","author":"Abou-el-Enein","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.intimp.2026.116867_bb0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101114","article-title":"Development of an automated manufacturing process for large-scale production of autologous T cell therapies","volume":"31","author":"Francis","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.intimp.2026.116867_bb0845","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","article-title":"In vivo CAR engineering for immunotherapy","volume":"25","author":"Li","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0850","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","volume":"25","author":"Bot","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2026.116867_bb0855","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.intimp.2026.116867_bb0860","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.jaci.2024.12.1066","article-title":"Chimeric antigen receptor–modified T-cell therapy: recent updates and challenges in autoimmune diseases","volume":"155","author":"Ca\u00ebl","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2026.116867_bb0865","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1462307","article-title":"The current socioeconomic and regulatory landscape of immune effector cell therapies","volume":"11","author":"Sainatham","year":"2024","journal-title":"Front. Med."},{"key":"10.1016\/j.intimp.2026.116867_bb0870","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1200\/JCO.2015.64.9970","article-title":"Bispecific T-cell engagers (BiTEs) as treatment of B-cell lymphoma","volume":"34","author":"Smits","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116867_bb0875","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-021-01067-5","article-title":"CAR-T cells and BiTEs in solid tumors: challenges and perspectives","volume":"14","author":"Edeline","year":"2021","journal-title":"J. Hematol. Oncol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926007137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926007137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:05:26Z","timestamp":1789243526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926007137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":175,"alternative-id":["S1567576926007137"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116867","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The evolution of CAR therapies across oncology and autoimmunity: mechanistic insights and therapeutic innovations","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116867","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116867"}}